JPMorgan Starts Mallinckrodt plc (MNK) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Mallinckrodt plc (MNK) Target Lifted to $77 at Jefferies
March 14, 2014 6:45 AM EDTJefferies analyst Anthony Petrone reiterated a Buy rating and lifted his price target on Mallinckrodt plc (NYSE: MNK) from $66 to $77.
Analyst Anthony Petrone said, "Lack of abuse deterrence in label does not dramatically alter our near-term outlook for the product;... More
Depomed (DEPO) Reports FDA Approval of XARTEMIS XR NDA
March 12, 2014 9:02 AM EDTDepomed, Inc. (Nasdaq: DEPO) announced that the U.S. Food and Drug Administration (FDA) approved Mallinckrodt plc's (NYSE: MNK) New Drug Application (NDA) for XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), previously known as MNK-795, for the management of acute pain severe enough to require opioid treatment and in patients for whom alternative... More
